Pierre Country
    • Homepage
Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference

Author: NS Pharma, Inc.

Posted Date:

March 9, 2026
  • Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference

    NS Pharma, Inc.
    March 9, 2026